In‐Stent Restenosis in the New Generation DES Era

Mennuni, Marco; Sagazio, Emanuele; Patti, Giuseppe

doi:10.1002/9781119697367.ch21

Cited by 1 publication

(2 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Scaffold fracture is a progressive condition linked with poor biocompatibility [17]. One of the main risk factors for stent fractures is the length of the stent (5 cm versus 3 cm) and the positioning of the stent in a bypass graft or the right coronary artery [18,19]. The conservative treatment of stent fractures without restenosis has shown favorable results [19].…”

Section: Introduction: From Coronary Balloon Angioplasty To Drug-elut...mentioning

confidence: 99%

“…One of the main risk factors for stent fractures is the length of the stent (5 cm versus 3 cm) and the positioning of the stent in a bypass graft or the right coronary artery [18,19]. The conservative treatment of stent fractures without restenosis has shown favorable results [19]. There is a problem known as malposition, which occurs when the struts of the stent are not aligned with the vessel surface.…”

Section: Introduction: From Coronary Balloon Angioplasty To Drug-elut...mentioning

confidence: 99%

See 1 more Smart Citation

Is There an Advantage of Ultrathin-Strut Drug-Eluting Stents over Second- and Third-Generation Drug-Eluting Stents?

Gherasie

Valentin

Busnatu

2023

JPM

View full text Add to dashboard Cite

In patients undergoing percutaneous coronary intervention, the second-generation drug-eluting stents (DES) are considered the gold standard of care for revascularization. By reducing neointimal hyperplasia, drug-eluting coronary stents decrease the need for repeat revascularizations compared with conventional coronary stents without an antiproliferative drug coating. It is important to note that early-generation DESs were associated with an increased risk of very late stent thrombosis, most likely due to delayed endothelialization or a delayed hypersensitivity reaction to the polymer. Studies have shown a lower risk of very late stent thrombosis with developing second-generation DESs with biocompatible and biodegradable polymers or without polymers altogether. In addition, research has indicated that thinner struts are associated with a reduced risk of intrastent restenosis and angiographic and clinical results. A DES with ultrathin struts (strut thickness of 70 µm) is more flexible, facilitates better tracking, and is more crossable than a conventional second-generation DES. The question is whether ultrathin eluting drug stents suit all kinds of lesions. Several authors have reported that improved coverage with less thrombus protrusion reduced the risk of distal embolization in patients with ST-elevation myocardial infarction (STEMI). Others have described that an ultrathin stent might recoil due to low radial strength. This could lead to residual stenosis and repeated revascularization of the artery. In CTO patients, the ultrathin stent failed to prove non-inferiority regarding in-segment late lumen loss and showed statistically higher rates of restenosis. Ultrathin-strut DESs with biodegradable polymers have limitations when treating calcified (or ostial) lesions and CTOs. However, they also possess certain advantages regarding deliverability (tight stenosis, tortuous lesions, high angulation, etc.), ease of use in bifurcation lesions, better endothelialization and vascular healing, and reducing stent thrombosis risk. In light of this, ultrathin-strut stents present a promising alternative to existing DESs of the second and third generation. The aims of the study are to compare ultrathin eluting stents with second- and third-generation conventional stents regarding procedural performance and outcomes based on different lesion types and specific populations.

show abstract

Section: Introduction: From Coronary Balloon Angioplasty To Drug-elut...mentioning

confidence: 99%

Section: Introduction: From Coronary Balloon Angioplasty To Drug-elut...mentioning

confidence: 99%

Is There an Advantage of Ultrathin-Strut Drug-Eluting Stents over Second- and Third-Generation Drug-Eluting Stents?

Gherasie

Valentin

Busnatu

2023

JPM

View full text Add to dashboard Cite

show abstract

In‐Stent Restenosis in the New Generation DES Era

Cited by 1 publication

References 116 publications

Is There an Advantage of Ultrathin-Strut Drug-Eluting Stents over Second- and Third-Generation Drug-Eluting Stents?

Is There an Advantage of Ultrathin-Strut Drug-Eluting Stents over Second- and Third-Generation Drug-Eluting Stents?

Contact Info

Product

Resources

About